Why 1 Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38%

1 hour ago 1

Selena Maranjian, The Motley Fool

Mon, May 25, 2026 astatine 5:05 AM CDT 4 min read

If you've spent immoderate clip speechmaking astir definite stocks, you'll person noticed that opinions among Wall Street analysts tin alteration widely. Because there's nary mode to definitively find wherever a banal volition beryllium successful the future, it's hard to cognize for definite that it's a buy, sell, oregon hold. It's the aforesaid with The Motley Fool: One of its writers mightiness beryllium precise bullish connected 1 stock, portion her workfellow is bearish. That's wherefore it's bully to work aggregate opinions and deliberation them done connected your own.

Here's 1 example: Pfizer (NYSE: PFE). The MarketWatch website precocious tracked 28 ratings for the stock: Nine Wall Street analysts said "buy," 1 said the banal was overweight (which fundamentally means it's a buy), 15 said "hold," and 3 said "sell." The consensus, then, was to hold.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

These ratings are occasionally changed oregon reaffirmed. Guggenheim Securities precocious reaffirmed its bargain standing for Pfizer, on with a terms people of $36 per share. That's afloat 38% higher than the caller stock terms of astir $26.

An seemingly huffy idiosyncratic is making calculations connected a wide board.

Ratings of buy, sell, oregon clasp are not arsenic invaluable to cognize arsenic the reasoning down them. Fortunately, the ratings are often accompanied by probe reports -- and galore bully brokerages connection their customers entree to specified reports for free.

Guggenheim says...

As with astir pharmaceutical companies, overmuch rides connected Pfizer's improvement pipeline -- which precocious featured 96 drugs successful development, 31 of those successful late-stage signifier 3. The Guggenheim analyst, Vamil Divan, was optimistic due to the fact that of encouraging results from immoderate late-stage objective trials of Pfizer drugs, and saw much upside than downside.

Divan cited upcoming information from the Mevpro-1 signifier 3 proceedings of mevrometostat, which treats metastatic castration-resistant prostate cancer. Results are expected successful the 2nd fractional of 2026. He expects astir $2 per stock upside if the proceedings succeeds, versus a downside of astir $1 if it doesn't.

The company's archetypal quarter, which it reported successful aboriginal May, was promising; CFO David Denton noted that "I'm peculiarly pleased with the 22% year-over-year operational gross maturation from our launched and acquired products." CEO Albert Bourla wrote that "Our R&D [research and development] pipeline is advancing connected aggregate fronts -- with affirmative Phase 3 readouts and encouraging mid-stage results gathering meaningful momentum -- and I'm peculiarly encouraged by what we're seeing successful oncology and obesity, 2 areas wherever I judge Pfizer is positioned to lead."

Read Entire Article